Lumito on BioStock’s list of the 10 strongest life science stocks 2022
BioStock has listed this year's ten strongest Swedish life science stocks and taken a closer look at some companies to see what's behind the share price increases. Lumito is ranked third on the list: "Lumito rises ahead of market launch High up on this year's winners list we also find diagnostics company Lumito, […]
Reflections from the Digital Pathology & AI Congress. Lumito – New kid in town
Lumito participated with a booth of our own at the Digital Pathology & AI Congress in London in early December. The congress was attended by over 440 delegates and was held at a conference hotel at Heathrow. The delegates, primarily from Western Europe, were specifically interested in the digitalization of pathology with both research and […]
The scientific article “Extracellular galectin 4 drives immune evasion and promotes T-cell apoptosis in pancreatic cancer” is now published in Cancer Immunology Research
The scientific article entitled "Extracellular galectin 4 drives immune evasion and promotes T-cell apoptosis in pancreatic cancer" is now published in the scientific journal Cancer Immunology Research. The main objective of the journal is to publish the best new findings from leading experts in chemistry, biology and clinical science. The paper is written by Daniel […]
The pre-launch phase of SCIZYS by Lumito continues without interruption
The pre-launch phase, which started in Spring 2022, continues and is now intensified as planned. Lumito will be represented with its own stand at the Digital Pathology & AI Congress: Europe in London on December 7-8. The presence at the congress will be complemented by advertising and editorial in the international professional journal The Pathologist […]
The launch of SCIZYS by Lumito will be slightly delayed
As previously communicated, Lumito's ambition and plan has been to offer product for researchers use only by the end of 2022. Employees and production partners have together set the plan and worked hard and focused on fulfilling the ambition, which has been deemed fully realistic until now. Lumito therefore wishes to inform that the launch […]
Testing the Lumito scanner with the final product design
Lumito's research and development team has attended the operational testing of the company's scanner with the final product design at the Swedish partner, Optronics Partner pr. Since a few months ago Lumito is in the commercialization phase with production as an area of focus. The purpose of the briefing was to test all the scanner's functions […]
Lumito – Associated Member of PathLAKE and part of the Consortium’s highly valuable network
Lumito's application for Associate Membership of the PathLAKE Consortium has been approved. The PathLAKE Consortium is a network of leading NHS Trusts and UK universities who, in collaboration with industrial partners, are at the forefront of innovation in digital pathology. The Consortium's work includes AI-driven diagnostics to increase the efficiency and effectiveness of pathology reporting […]
Preliminary study to detect immune complex and complement deposits in renal biopsies initiated with the University Hospitals Coventry and Warwickshire in the UK
A proof of concept-study to explore the potential of Lumito's UCNP to detect immune complex and complement deposits in renal biopsies has been initiated in collaboration with University Hospitals Coventry and Warwickshire NHS Trust in the UK and a research team led by Dr. Kishore Gopalakrishnan. Obtaining a renal biopsy is an invasive procedure […]
Booth at the European Congress of Pathology – a step towards commercialisation
For the first time ever, Lumito will have its own booth at a pathology congress. Booth number 79 has been booked for the European Congress of Pathology, which will take place in Basel from 3-7 September. "We are now ready to expose our product at one of Europe's busiest trade fairs for pathologists and other […]
Letter of Intent signed with Kaivogen Oy to produce Lumito’s complete reagent kits
Lumito AB and the Finnish company Kaivogen Oy have signed a Letter of Intent to produce Lumito's immunohistochemistry reagent kit, which is part of the company's complete product offering in digital tissue analysis. The ambition is to launch the product in research laboratories in the latter part of 2022. Lumito's product consists of a scanner […]
